Effect of Microbiome Modulation by Diet in Functional Constipation

NCT05429333 | Completed

• 1 other identifier: 10840098-772.02-E.47859
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

Current medications and behavioral modifications have limited success in the treatment of functional constipation (FC). An individualized diet based on microbiome analysis may improve symptoms in FC. In the present study, we aimed to investigate the impacts of microbiome modulation on chronic constipation. patients fulfilling Rome IV criteria for functional constipation were randomized into two groups. The Control group received sodium picosulfate plus conventional treatments (i.e., laxatives, enemas, increased fiber, and fluid intake). The study group underwent microbiome analysis and received an individualized diet with the assistance of a soft computing system (Enbiosis Biotechnology®, Sariyer, Istanbul). Differences in Patient Assessment Constipation-Quality of Life (PAC-QoL) score and complete bowel movements per week (CBMpW) were compared between groups after 6 week-intervention.

Conditions

Constipation - Functional

Keywords

Microbiome; Artificial intelligence; Diet; Functional bowel disorders; Brain-gut diseases

Outcome Measures

Primary Outcomes (2)

• Three or more complete bowel movements per week at 10 weeks

  The proportion of patients with a mean of three or more complete bowel movements per week (CBMpW) at 10 weeks is compared between control and study groups.

  10 weeks

• Improvement in Patient Assessment Constipation Quality of Life

  The proportion of the patients with more than 50% improvement in total Patient Assessment Constipation Quality of Life score is compared between control and study groups.

  10 weeks

Study Arms (2)

Control group

NO INTERVENTION

After randomization control group was recommended to continue their regular diet with increased fluid (2 lt/day) and fiber intake (30 g/day) and received 5 mg of sodium picosulfate daily for 10 weeks.

Treatment group

EXPERIMENTAL

In the study group, after fecal samples were taken, patients were recommended to continue their regular diet with increased fluid (2 lt/day) and fiber intake (30 g/day) for 4 weeks until the microbiome analysis resulted. During subsequent 6 weeks, they received the personalized microbiome modulatory diet.

Other: Artificial intelligence-assisted personalized diet

Interventions

Artificial intelligence-assisted personalized diet OTHER

The AI-based nutritional recommendations system is based on the eating rates of the individual in a certain period, to ensure the homeostasis of the microbiome and increase the microbial diversity. After the microbiome analysis reports of the study group are released, a 6-week diet was designed regarding AI-based food scores specific to constipated individuals in accordance with the individual's lifestyle and comorbidities. Diet lists are updated according to the individual's feedback, recovery level, and wishes with weekly meetings.

Treatment group

Eligibility Criteria

• Age: 20 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients fulfilling Rome IV criteria for functional constipation (FC)
• Patients who had a colonoscopy performed within the last 5 years
• Patients who had a colonic transit time assessment within the last 3 months
• Patients who had a magnetic resonance defecography within the last 3 months

You may not qualify if:

• Use of antibiotics, probiotics, and/or prebiotics within the last 4 weeks
• Gastrointestinal endoscopy within the last 4 weeks
• Major gastrointestinal surgery (total/segmental gastrectomy, small bowel and/or colonic resection)
• Cholecystectomy
• Inflammatory bowel diseases
• Celiac disease
• Any etiology of chronic constipation other than FC (irritable bowel syndrome, rectocele, dyssynergic defecation, opioid use)
• Endocrine, metabolic or neurologic disorders causing constipation (hypothyroidism, Parkinson's disease, paraplegia)

Sponsors & Collaborators

• Istanbul Medipol University Hospital: lead

Study Sites (1)

Medipol University Esenler Hospital

Istanbul, Other (Non U.s.), 34230, Turkey (Türkiye)

Location

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 17, 2022
• First Posted: June 23, 2022
• Study Start: December 14, 2020
• Primary Completion: December 27, 2021
• Study Completion: December 27, 2021
• Last Updated: June 23, 2022

Record last verified: 2022-06

Locations

TU (1)